Shopping Cart
Remove All
Your shopping cart is currently empty
Leronlimab (Alias: PRO 140)
Catalog No. T77059 Copy Product Info
🥰Excellent
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
Leronlimab
Copy Product Info🥰Excellent
Catalog No. T77059
Alias PRO 140
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
Leronlimab
Cas No. 674782-26-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $198 | In Stock | In Stock | |
| 5 mg | $579 | - | In Stock | |
| 10 mg | $928 | - | In Stock | |
| 25 mg | $1,370 | - | In Stock | |
| 50 mg | $1,850 | - | In Stock | |
| 100 mg | $2,480 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95% (SDS-PAGE); 99.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer. |
| In vitro | Leronlimab (1-140 mg/mL) binds to CCR5-positive cells up to 98% and (80-1750 μg/mL) inhibits calcium response induced by CCL5, CCL3, and CCL4 in MDA-MB-231 cells. Additionally, Leronlimab (175 and 350 mg/mL) blocks the invasion of MDA-MB-231 cells and (10 μg/mL; 72 hours) enhances the cytotoxicity of doxorubicin against these cells[1]. |
| In vivo | Leronlimab (2 mg; intraperitoneal injection; twice a week) reduces lung metastasis in a mouse xenograft model[1]. |
| Synonyms | PRO 140 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CCR5/CD195 |
| Molecular Weight | 146.66 kDa |
| Cas No. | 674782-26-4 |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Leronlimab | purchase Leronlimab | Leronlimab cost | order Leronlimab | Leronlimab in vivo | Leronlimab in vitro | Leronlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.